Recent reports indicate that early failure of transplanted hearts accounts for 20% of the total mortality following cardiac transplantation today. We believe that such early failure can be prevented by T3 therapy to both donor and recipient, and we recommended the routine use of such therapy in all donors and recipients of cardiac allografts.
